UCB S.A.
UCB
Classifica tra le azioni
#507
UCB S.A., a biopharmaceutical enterprise founded in 1925 and headquartered in... UCB S.A., a biopharmaceutical enterprise founded in 1925 and headquartered in Brussels, Belgium, focuses on developing innovative solutions for individuals living with neurological and immunological diseases. Its diverse commercialized portfolio includes Cimzia, targeting inflammatory TNF-mediated conditions such as Crohn's disease, various forms of spondyloarthritis, rheumatoid arthritis, and psoriasis. For epilepsy management, UCB offers Vimpat, Keppra, and Briviact, along with Nayzilam, an intranasal rescue treatment for seizure clusters. Neupro is available for Parkinson's disease and restless legs syndrome, while Zyrtec and Xyzal address allergy symptoms. Other key products include Evenity for osteoporosis in postmenopausal women, and BIMZELX, which treats psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa. The company also provides dapirolizumab pegol for systemic lupus erythematosus. UCB's robust development pipeline features candidates like rozanolixizumab, aimed at myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan for myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam for prolonged seizures; Bepranemab for Alzheimer's disease; and UCB0599 for Parkinson's disease. Beyond its proprietary drug development, UCB also conducts contract manufacturing. The company engages in significant collaborations with entities such as Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. UCB's global footprint extends across numerous countries, including the United States, Japan, China, Belgium, and a broad presence throughout Europe, encompassing Germany, Spain, France, Italy, the United Kingdom, and Ireland.
Prezzo delle azioni
$249.09
Capitalizzazione di mercato
$47.49B
Variazione (1 giorno)
2.34%
Variazione (1 anno)
-15.54%
Paese
BE
Scambia UCB S.A. (UCB)
Categoria
Healthcare
Rapporto P/B per UCB S.A. (UCB)
Rapporto P/B al October 2026 TTM: 3.29
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di UCB S.A., il rapporto P/B attuale (TTM) è 3.29. Alla fine del 2023, era pari a 1.67.
Storico del rapporto P/B per UCB S.A. da 2002 a 2026
Rapporto P/B alla fine di ogni anno
| Anno | Rapporto P/B | Cambia |
|---|---|---|
| 2026 (TTM) | 3.29 | -9.53% |
| 2024 | 3.64 | 117.45% |
| 2023 | 1.67 | 8.75% |
| 2022 | 1.54 | -31.95% |
| 2021 | 2.26 | 2.95% |
| 2020 | 2.20 | 16.48% |
| 2019 | 1.89 | -11.46% |
| 2018 | 2.13 | -1.68% |
| 2017 | 2.17 | 5.43% |
| 2016 | 2.05 | -27.10% |
| 2015 | 2.82 | 17.13% |
| 2014 | 2.41 | 8.68% |
| 2013 | 2.21 | 31.28% |
| 2012 | 1.69 | 30.59% |
| 2011 | 1.29 | 28.19% |
| 2010 | 1.01 | -15.51% |
| 2009 | 1.19 | 13.99% |
| 2008 | 1.05 | -20.21% |
| 2007 | 1.31 | -20.05% |
| 2006 | 1.64 | -30.63% |
| 2005 | 2.36 | -14.48% |
| 2004 | 2.76 | 13.04% |
| 2003 | 2.45 | -29.19% |
| 2002 | 3.45 | 0.00% |
Rapporto P/B per aziende simili o concorrenti
| Azienda | Rapporto P/B | Differenza del rapporto P/B | Il paese |
|---|---|---|---|
| 6.251 | 89.82% |
US
|
|
| 13.2547 | 302.49% |
US
|
|
| 4.208 | 27.78% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | 87.73% |
NL
|
